Failure Patterns: The Investor’s Guide to Cardiac AI Exits

The pathway to a viable exit for a cardiac imaging startup is paved with a carefully documented record of clinical evidence, not funding announcements. For investors looking at pre-IPO AI health companies, especially in the cardiac imaging space, the job is to learn how to see past the headlines and find that substance. A “failure pattern” analysis, which is just a fancy way of saying you’re grounding your evaluation in verifiable public documents, provides a strong framework for judging a company’s potential, particularly when you contrast it with the optimistic stories private digital health companies tell.

The Non-Negotiable Documentation for Cardiac Imaging Startups

Before a cardiac imaging startup can even start talking about market penetration or growth, it needs to have its foundational documents in order. This is about building a verifiable narrative that holds up when people start digging. For any AI-driven SaMD in cardiology, this includes a clear path through regulatory bodies like the FDA. The most common route is a 510(k) clearance, which demonstrates the device is substantially equivalent to something already on the market FDA 510(k) pathway explanation. Truly new AI functions, however, might require a De Novo classification, a much longer but equally critical process. Beyond just regulatory milestones, a strong Quality Management System (QMS), often one that’s ISO 13485-certified, is an expected piece of the puzzle that signals operational maturity to investors during technical due diligence. Without these fundamental elements, a company’s claims are just hot air, no matter how much funding it has raised.

Clinical Evidence Moat: The True Barrier to Entry

A Clinical Evidence Moat for cardiac imaging AI means having a continuous, documented commitment to showing real-world efficacy and impact that goes far beyond getting an initial regulatory clearance. This moat is built through rigorous clinical studies, the kind that get published in peer-reviewed journals such as the JAMA Network JAMA Network publications on cardiovascular AI. Investors should be looking for hard evidence of how the AI performs in diverse patient populations, its actual impact on clinical workflows, and its contribution to better patient outcomes. You have to distinguish between Clinical Decision Support (CDS) and Diagnostic AI. CDS provides recommendations and is often less regulated, while Diagnostic AI makes independent determinations and is regulated as a full-on medical device. The evidence bar for Diagnostic AI is significantly higher. A strong Clinical Evidence Moat is also reflected in the company’s pursuit of CPT codes, particularly Category I, which show there are established reimbursement pathways. Without this demonstrable evidence, even a technically impressive AI solution faces an impossible battle for widespread adoption and sustainable revenue, regardless of its initial “wedge product” strategy.

The Recorded Failure Set: Cleerly and AliveCor in Focus

The “Startup Failure Pattern” frame forces a sobering, document-first reading of a cardiac imaging startup’s trajectory, pushing past PR-driven stories to focus on recorded facts. This frame is especially useful when examining companies like Cleerly and AliveCor, both of which appear in the documented failure set based on verifiable public records. For AliveCor, its record includes extensive litigation and regulatory challenges concerning its KardiaMobile device. AliveCor was tied up in significant legal disputes with Apple over patent infringement and competitive practices, with Apple largely winning on patent invalidation and antitrust claims by early 2026, though other legal proceedings continue. Public filings with the US Securities and Exchange Commission (sec.gov) detail these ongoing legal battles SEC filings for AliveCor. These documented challenges, not just anecdotal reports, show a company grappling with fundamental issues that affect its long-term viability and potential for a successful exit. The existence of these records provides a tangible basis for assessing risk, showing how a company’s actions and responses to regulatory and competitive pressures can define its future. Cleerly, while a prominent name in cardiac CT imaging, has also had a documented journey. The company received FDA Breakthrough Device Designation for its Coronary Artery Disease (CAD) Staging System in March 2024 and FDA clearance for Cleerly LABS v2.0 in March 2025, and Aetna approved coverage for its AI analysis in January 2026. These developments, when you look at them through the lens of verifiable records, show the absolute necessity of a strong Clinical Evidence Moat and a clear regulatory strategy. The focus here isn’t on financial figures or funding rounds. It’s on the type of documented issues that emerge and how they impact the company’s perceived stability and trustworthiness. The recorded signals for this frame, the Clinical Evidence Moat, IPO Candidate status, and adherence to the FDA Digital Health Framework, are objective markers that can be tracked and verified.

Signals Beyond the Hype: IPO Candidate and FDA Digital Health Framework

For investors eyeing pre-IPO AI health companies, two more critical signals offer additional layers of verifiable insight: IPO Candidate status and alignment with the FDA Digital Health Framework. In this context, an “IPO Candidate” isn’t a self-proclaimed ambition but is inferred from a company’s documented maturity, governance, and sustained regulatory compliance. A company truly on an IPO path exhibits a transparent and well-managed approach to its intellectual property, avoiding the creation of a “patent thicket” that could bog down future growth or attract expensive litigation. The FDA Digital Health Framework, which includes principles like GMLP (Good Machine Learning Practice) and the concept of a PCCP (Predetermined Change Control Plan), is another non-negotiable benchmark. Is the company actually following it? Adherence to this framework shows a forward-thinking approach to AI development, acknowledging the baked-in challenges of algorithmic drift and the need for continuous model improvement within a regulated environment. Companies that proactively build to these principles are demonstrating a commitment to long-term safety and efficacy, reducing “regulatory debt” that could otherwise become a huge liability. The absence of clear, documented strategies around these frameworks, especially when you pair it with a weak Clinical Evidence Moat, can signal deep vulnerabilities that may derail an exit strategy.

What Investors Can Check Without a Vendor Conversation

The read for investors is clear: a viable exit path and a strong growth trajectory for a cardiac imaging startup rest on the clinical evidence record, not on the glow of a funding headline. This is the line between a funding story and a funding record. Investors can independently verify several critical elements without relying on what the vendor tells them. First, scrutinize public databases for regulatory clearances on FDA.gov. Is the device a SaMD? What is its classification (510(k), De Novo, Breakthrough Device Designation)? Second, search peer-reviewed literature like the JAMA Network and PubMed for publications detailing clinical trials, real-world evidence (RWE), and outcomes data. Is the Clinical Evidence Moat substantial and continually being reinforced? Third, for companies with a longer history, dig into US Securities and Exchange Commission (sec.gov) filings for any legal or regulatory challenges that have been formally documented. These public records provide a raw view of a company’s operational realities, offering a documented basis for assessing risk and potential. By focusing on these verifiable facts, investors can get past the aspirational claims and ground their decisions in a concrete understanding of a cardiac imaging startup’s true standing and exit potential.